Adlai Nortye Ltd. said it has announced clinical trial notification submission and HREC approval for the Phase I clinical trial of pan-RAS(ON) inhibitor ADC AN4035 in Australia.
Adlai Nortye said it is in process of IND submissions for AN4035 to the U.S. FDA and China NMPA.
ANL•
